Company Filing History:
Years Active: 2021-2024
Title: Xuemei Yu: Innovator in Glucose Uptake Inhibitors
Introduction
Xuemei Yu is a notable inventor based in Livingston, NJ (US). He has made significant contributions to the field of medical research, particularly in the development of glucose uptake inhibitors. With a total of 2 patents, his work focuses on innovative solutions for treating various diseases.
Latest Patents
Xuemei Yu's latest patents include groundbreaking inventions aimed at modulating glucose uptake activity. One of his notable inventions is a compound that targets glucose transporters, specifically GLUTS3, and also includes GLUT1-14 (SLC2A1-SLC2A14). This invention is particularly useful for treating diseases such as cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic disorders. Another significant patent involves methods for treating inflammatory conditions and autoimmune diseases in mammals. This method comprises administering a therapeutically effective amount of a glucose uptake inhibitor, which modulates the glucose transport of GLUT1 and GLUT3.
Career Highlights
Xuemei Yu is currently associated with Kadmon Corporation, LLC, where he continues to advance his research and innovations. His work has the potential to impact the treatment landscape for various diseases significantly.
Collaborations
Xuemei Yu collaborates with talented individuals such as Ji-In Kim and Kellen L Olszewski, contributing to a dynamic research environment.
Conclusion
Xuemei Yu's innovative work in glucose uptake inhibitors showcases his commitment to advancing medical science. His contributions are paving the way for new treatments that could benefit many patients in need.